Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study ; volume:22 ; number:1 ; day:13 ; month:12 ; year:2023 ; pages:1-12 ; date:12.2023
Cardiovascular diabetology ; 22, Heft 1 (13.12.2023), 1-12, 12.2023
- Urheber
-
Simon, Tracey G.
Ebrahimi, Fahim
Roelstraete, Bjorn
Hagström, Hannes
Sundström, Johan
Ludvigsson, Jonas F.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-023-02070-5
- URN
-
urn:nbn:de:101:1-2024022810445917869866
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Simon, Tracey G.
- Ebrahimi, Fahim
- Roelstraete, Bjorn
- Hagström, Hannes
- Sundström, Johan
- Ludvigsson, Jonas F.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Early-life antibiotic exposure aggravate the metabolic dysfunction-associated steatotic liver disease associated hepatocellular carcinoma
Atrial tachy-arrhythmias associated with massive edema in the newborn
Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
Steatotic liver disease associated with 2,4-dienoyl-CoA reductase 1 deficiency
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Early-life antibiotic exposure aggravate the metabolic dysfunction-associated steatotic liver disease associated hepatocellular carcinoma
Atrial tachy-arrhythmias associated with massive edema in the newborn
Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
Steatotic liver disease associated with 2,4-dienoyl-CoA reductase 1 deficiency
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease
Ferroptosis is a targetable detrimental factor in metabolic dysfunction-associated steatotic liver disease
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
Early-life antibiotic exposure aggravate the metabolic dysfunction-associated steatotic liver disease associated hepatocellular carcinoma
Atrial tachy-arrhythmias associated with massive edema in the newborn
Targeted metabolomics reveals plasma short-chain fatty acids are associated with metabolic dysfunction-associated steatotic liver disease
Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk: a comprehensive review
Interplay between YAP/TAZ and metabolic dysfunction-associated steatotic liver disease progression
Single‐cell transcriptomics stratifies organoid models of metabolic dysfunction‐associated steatotic liver disease
Effects of semaglutide-loaded lipid nanocapsules on metabolic dysfunction-associated steatotic liver disease
Steatotic liver disease associated with 2,4-dienoyl-CoA reductase 1 deficiency
IFNγ-IL12 axis regulates intercellular crosstalk in metabolic dysfunction-associated steatotic liver disease